Business

Event Cardio Group Advances its Commercialization of NowCardio™ in Europe, Australia and the U.S. and receives $325,000 CAD

Event Cardio Group Advances its Commercialization of NowCardio™ in Europe, Australia and the U.S. and receives $325,000 CAD.

articleEcgi Holdings Inc.March 1, 20165/company/ecgi-holdings-inc/news/event-cardio-group-advances-its-commercialization-of-nowcardiotm-in-europe-australia-and-the-us-and-receives-dollar325000-cad-1
Event Cardio Group Advances its Commercialization of NowCardio™ in Europe, Australia and the U.S. and receives $325,000 CAD

About this update from Ecgi Holdings Inc.

[{"type":"text","content":"March 1, 2016Event Cardio Group Advances its Commercialization of NowCardio™ in Europe, Australia and the U.S. and receives $325,000 CADNEW YORK, NY--(Marketwired – February 23rd, 2016) - Event Cardio Group, Inc. (OTCQB: ECGI), a medical device company, that has developed  NowCardio™,  an    Advanced Ambulatory Arrhythmia Monitoring System, is pleased to announce it has entered into a support agreement with The Stornoway Group, Inc.\tEvent Cardio Group Inc. has signed an agreement with The Stornoway Group, Inc. for support in obtaining the regulatory approvals necessary to market the NowCardio™ medical device in Europe, Australia and the U.S. The support includes assistance with ISO 13485:2003 (CMDCAS & MDD) quality management system (QMS) documentation, 21 CFR Part 807 implementation, and support through to compliance audits of the QMS by the Registrar / Approval Authorities (FDA/TGA). The scope covers the design, manufacture, packaging, instructions for use, labeling, and customer support of the NowCardio™, medical device.Event Cardio Group has a second tranche of $325,000 CAD from the group of individuals with which it entered into Subscription Agreements for a total of $1,500,000 as previously disclosed in a Report on Form 8-K filed February 17, 2016.  To date, the group has advanced $660,000 CAD of the $1,500,000 CAD provided for in the Subscription Agreements.  This wsecond tranche of funds will largely be used to further the commercialization of the NowCardio™ medical device.John Bentivoglio, Chief Executive Officer and President of Event Cardio Group, stated, \"I am extremely pleased to move forward with the certification and plan for the distribution of NowCardio™ in Europe, Australia and the U.S. These markets are strategically important to the commercialization plans for NowCardio™, and our partner in Australia looks forward to distributing NowCardio™ as soon as the regulatory process is completed.\"About Event Cardio Group, Inc.Event Cardio Group, Inc. is a developer of medical diagnostic detection equipment that focuses on the detection, and preventive treatment, of high-risk diseases. The Company's core product is NowCardio™,an advanced Advanced Ambulatory Arrhythmia Monitoring System monitor which offers the combined functionality of holter monitoring, event recording, and mobile ...

More updates from Ecgi Holdings Inc.